Voglio sapere a riguardo di…

12007

Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices RF Program Entrance Survey for Reentering Fathers.
Exit survey, with five versions: 1
HM Program Exit Survey for AdultFocused Programs; 2 HM Program Exit Survey for Youth-Focused Programs; 3
RF Program Exit Survey for CommunityBased Fathers; 4 RF Program Exit Survey for Community-Based Mothers;
and 5 RF Program Exit Survey for Reentering Fathers.
The measures used by the 2015
grantee cohort were developed in 2014
after extensive review of the research literature and grantees past measures.
The performance measures, data collection instruments, and data collection system were revised in 2020

based on a targeted analysis of existing measures, feedback from key stakeholders, and discussions with ACF
staff and the 2015 cohort of grantees.
ACF required the 2015 cohort of grantees to submit data on these standardized measures on a quarterly basis and proposes the same requirement for the 2020 cohort. In addition to the performance measures mentioned above, ACF proposes to repeat collection for these data submissions:
Semi-annual Performance Progress Report PPR, with two versions: 1
Performance Progress Report for HM
Programs, and 2 Performance Progress Report for RF Programs; and
Quarterly Performance Report QPR, with two versions: 1 Quarterly Performance Progress Report for HM
Programs, and 2 Quarterly Performance Progress Report for RF
Programs.
Grantees in the new cohort will also be required to engage in continuous quality improvement CQI planning and implementation using a proposed CQI plan template developed by ACF.
The estimated burden for completing and updating this template is included in the table below.
Respondents: Respondents include HM and RF grantee staff and program applicants and participants participants are called clients.

ANNUAL BURDEN ESTIMATES
Number of responses per respondent total over request period
Number of respondents total over request period
Average burden per response in hours
Total burden in hours
Annual burden in hours
Instrument
Respondent
1: Applicant Characteristics

Program applicants
Program staff
Program staff
Program staff
Program clients entrance
Program clients exit
Program staff entrance and exit on paper.
Program staff

273,840
408
136
2,040
257,409
169,965
32

1
672
12
126
1 1
3,506

0.25
0.10
0.32
0.50
0.42
0.42
0.10

68,460.0
27,417.6
522.24
128,520.0
108,111.78
71,385.3
11,219.2

22,820.0
9,139.2
174.08
42,840.0
36,037.26
23,795.1
3,739.73

136

6

3

2,448.0

816.0

Program staff

136

6

1

816.0

272.0

Program staff

136

3

4

1,632

544.0

2: Program Operations
3: Service Delivery Data
4: Entrance and Exit Surveys

5: Semi-annual Performance Progress Report PPR.
6: Quarterly Performance Report QPR.
7: CQI Plan

patent applications may be obtained by emailing Brian W. Bailey, Ph.D., bbailey@mail.nih.gov, the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD
208922479; telephone: 3014025579.
A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows.

Estimated Total Annual Burden Hours: 140,177.37.
Authority: Sec. 403. 42 U.S.C. 603.
Mary B. Jones, ACF/OPRE Certifying Officer.
FR Doc. 202104162 Filed 22621; 8:45 am BILLING CODE 418473P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Government-Owned Inventions;
Availability for Licensing AGENCY:

Use of Statins To Treat or Prevent DrugInduced Hearing Loss
National Institutes of Health,
Description of Technology
HHS.
ACTION:

Notice.

The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of SUMMARY:

VerDate Sep<11>2014

18:48 Feb 26, 2021

Jkt 253001

Available for licensing and commercial development are patent rights covering methods of using atorvastatin and related statin compounds and derivatives to reduce or prevent drug-induced hearing loss that is caused as a side effect by ototoxic drugs such as cisplatin, which is commonly used in cancer therapies. At present, permanent hearing loss occurs in approximately half of all patients
PO 00000

Frm 00089

Fmt 4703

Sfmt 4703

treated with cisplatin; consequently, every year many thousands of individuals experience partial loss of hearing and associated quality of life issues as a result of medically necessary chemoradiation therapies to treat their cancers. This technology addresses a large unmet need to eliminate or reduce hearing loss in patients that must undergo therapies involving ototoxic drugs.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications Repurposing existing statins, including atorvastatin, to treat or protect against permanent hearing loss arising from chemoradiation therapy involving ototoxic drugs.
Development of statin analogues or derivatives with enhanced abilities to treat or protect against hearing loss resulting from therapies involving cisplatin or other ototoxic drugs.

E:FRFM01MRN1.SGM

01MRN1